2023 Approvals
FDA Approves Zilbrysq for Myasthenia Gravis on October 17, 2023
What is Zilbrysq prescribed for? Zilbrysq is prescribed to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive. What is Zilbrysq and what does it do? Zilbrysq, pronounced zIL-brisk, (generic name: zilucoplan) is a new medication approved by the FDA for treating adults with a condition